FORM PTO-1449

Att. Docket No. REG 980A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.

REG 980A

Serial No.

to be assigned 10/758,798

Applicant:

Stanley J. Wiegand et al.

Date Filed

Concurrently herewith

For

METHODS OF IDENTIFYING

MODULTORS OF NMUR2-MEDIATED

ACTIVITY

Examiner

Not Yet Known Jon M. Lockard

Group Art Unit

Not Yet Known /6 47

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

Examiner	Patent	Patent	<u>Name</u>	Class/	Filing
<u>Initials</u>	<u>Number</u>	<u>Date</u>		Subclass	<u>Date</u>
mic	6,461,836	Oct. 8, 2002	Elshourbagy	et al.	Apr. 10, 2000

FOREIGN PATENT DOCUMENTS

Examiner	Document			Class/	Translation	
<u>Initials</u>	<u>Number</u>	<u>Date</u>	Country	<u>Subclass</u>	Yes No	

Jon m fall

3/20/66

REG 980A
USSN to be assigned 10/758.798
PTO 1449 Form
Wiegand, et al.
Page 2

OTHER DOCUMENTS

Examiner Initials

My/

MC Raddatz, et al., J. Biol. Chem. Vol. 275, No. 42, pp. 32452-32459

(2000)

MC Howard, et al., Nature, vol. 406, pp. 71-74, (2000)

Shan et al., J. Biol. Chem., Vol. 275, No. 50, pp 39482-39486, (2000)

EXAMINER CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Valeta Gregg Reg. No. 35,127

Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



FORM PTO-1449

Att. Docket No. REG 980A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.

REG 980A

Serial No.

10/758,798

Applicant:

Wiegand et al.

Date Filed

January 16, 2004

For

Methods of Identifying Modulators of

NMUR2-Mediated Activity

Examiner

to be assigned Ion M. Locker

Group Art Unit

to be assigned 16 47

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

Examiner	Patent	Patent	<u>Name</u>	Class/	Filing
<u>Initials</u>	<u>Number</u>	<u>Date</u>		<u>Subclass</u>	<u>Date</u>

FOREIGN PATENT DOCUMENTS

Examiner <u>Initials</u>	Document <u>Number</u>	<u>Date</u>	Country	Class/ Subclass	Transla <u>Yes</u>	ation <u>No</u>
MC	GB 2363793A	09 Jan. 2002	Great Brit	ian		
	WO 01/25269A 12 April 2001 PCT					
	EP 1237001A	04 Sept. 2002	2 Europe			
mc	WO 01/81418A	A 01 Nov. 200	1 PCT			

Am mille

3/20/06

REG 980 USSN 10/758,798 PTO 1449 Form Page 2

me

EP 1365246A 26 Nov. 2003 Europe

OTHER DOCUMENTS

Examiner Initials

MC Funes, S., et al. (2002) Peptides, Vol. 23, pp. 1607-1615.

Raddatz, R., et al. (2000) J. Biol. Chem., Vol. 275, No. 42, pp. 32452-32459. Do Not Print

MC Shan, L.X., et al. (2000) J. Biol. Chem., Vol. 275, No. 50, pp. 39482-

39486. Deplicate, Do NOT Print.

My Cao, C.Q., et al. (2003) PAIN, Vol. 104, pp. 609-616.

EXAMINER CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Valeta Gregg

Reg. No. 35,127

Attorneys for Applicant Patent Agent for Applicant Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591

(914) 345-7400